Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

29 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Outcomes and predictive value of the 2MACE score in patients with atrial fibrillation treated with rivaroxaban in a prospective, multicenter observational study: The EMIR study.
Sanmartín Fernández M, Anguita Sánchez M, Arribas F, Barón-Esquivias G, Barrios V, Cosin-Sales J, Esteve-Pastor MA, Freixa-Pamias R, Lekuona I, Pérez-Cabeza AI, Ureña I, Vázquez Rodríguez JM, Rafols Priu C, Marin F. Sanmartín Fernández M, et al. Cardiol J. 2022;29(4):601-609. doi: 10.5603/CJ.a2022.0044. Epub 2022 May 27. Cardiol J. 2022. PMID: 35621092 Free PMC article.
Epidemiology of atrial fibrillation-related ischemic stroke and its association with DOAC uptake in Spain: first national population-based study 2005 to 2018.
Díaz-Guzmán J, Freixa-Pamias R, García-Alegría J, Pérez Cabeza AI, Roldán-Rabadán I, Antolin-Fontes B, Rebollo P, Llorac A, Genís-Gironés M, Escobar-Cervantes C. Díaz-Guzmán J, et al. Rev Esp Cardiol (Engl Ed). 2022 Jun;75(6):496-505. doi: 10.1016/j.rec.2021.07.009. Epub 2021 Sep 10. Rev Esp Cardiol (Engl Ed). 2022. PMID: 34518112 Free article. English, Spanish.
Use of rivaroxaban attenuates renal function impairment in patients with atrial fibrillation: insights of the EMIR study.
López-Gálvez R, Rivera-Caravaca JM, Anguita Sánchez M, Sanmartín Fernández M, Rafols C, Pérez-Cabeza AI, Barón Esquivias G, Lekuona Goya I, Vázquez Rodríguez JM, Cosín Sales J, Arribas Ynsaurriaga F, Barrios V, Freixa-Pamias R, Marín F. López-Gálvez R, et al. Eur J Clin Invest. 2022 Sep;52(9):e13788. doi: 10.1111/eci.13788. Epub 2022 Apr 14. Eur J Clin Invest. 2022. PMID: 35395094
Rivaroxaban for the prevention of outcomes in patients with atrial fibrillation in clinical practice: an indirect comparison of national and international registries.
Marin F, Fernández MS, Lekuona I, Arribas F, Barón-Esquivias G, Barrios V, Cosin-Sales J, Freixa-Pamias R, Masjuan J, Pérez-Cabeza AI, Schilling VR, Vázquez Rodríguez JM, Priu CR, Sánchez MA. Marin F, et al. Among authors: freixa pamias r. J Comp Eff Res. 2022 Nov;11(16):1173-1184. doi: 10.2217/cer-2022-0111. Epub 2022 Sep 23. J Comp Eff Res. 2022. PMID: 36148923 Free article.
Impact of heart failure on the clinical profile and outcomes in patients with atrial fibrillation treated with rivaroxaban. Data from the EMIR study.
Anguita Sánchez M, Marín F, Masjuan J, Cosín-Sales J, Vázquez Rodríguez JM, Barrios V, Barón-Esquivias G, Lekuona I, Pérez-Cabeza AI, Freixa-Pamias R, Parra Jimenez FJ, Monzer Khanji Khatib M, Rafols Priu C, Sanmartín Fernández M. Anguita Sánchez M, et al. Among authors: freixa pamias r. Cardiol J. 2022;29(6):936-947. doi: 10.5603/CJ.a2022.0091. Epub 2022 Oct 6. Cardiol J. 2022. PMID: 36200548 Free PMC article.
Predicting performance of the HAS-BLED and ORBIT bleeding risk scores in patients with atrial fibrillation treated with Rivaroxaban: Observations from the prospective EMIR Registry.
Esteve-Pastor MA, Rivera-Caravaca JM, Roldán V, Sanmartin Fernández M, Arribas F, Masjuan J, Barrios V, Cosin-Sales J, Freixa-Pamias R, Recalde E, Pérez-Cabeza AI, Manuel Vázquez Rodríguez J, Ràfols Priu C, Anguita Sánchez M, Lip GYH, Marin F. Esteve-Pastor MA, et al. Among authors: freixa pamias r. Eur Heart J Cardiovasc Pharmacother. 2022 Dec 15;9(1):38-46. doi: 10.1093/ehjcvp/pvac060. Eur Heart J Cardiovasc Pharmacother. 2022. PMID: 36318457
Non-embolic outcomes in patients with cardiovascular disease and atrial fibrillation treated with rivaroxaban.
Marín F, Fernández MS, Barón-Esquivias G, Barrios V, Lekuona I, Pérez-Cabeza AI, Masjuan J, Del Vigo ER, Vázquez Rodríguez JM, Freixa-Pamias R, Schilling VR, Arribas F, Priu CR, Sánchez MA. Marín F, et al. Among authors: freixa pamias r. J Comp Eff Res. 2023 Mar;12(3):e220049. doi: 10.57264/cer-2022-0049. Epub 2023 Feb 7. J Comp Eff Res. 2023. PMID: 36749006 Free PMC article.
Adverse Clinical Outcomes and Associated Predictors in Rivaroxaban-Treated Atrial Fibrillation Patients With Renal Impairment.
Rivera-Caravaca JM, Anguita Sanchez M, Sanmartín Fernández M, Rafols C, Barón-Esquivias G, Arribas Ynsaurriaga F, Freixa-Pamias R, Lekuona Goya I, Vázquez Rodríguez JM, Pérez-Cabeza AI, Cosín-Sales J, Ureña Montilla I, Álvarez-Vieitez Blanco A, Marín F. Rivera-Caravaca JM, et al. Among authors: freixa pamias r. Am J Cardiol. 2023 Sep 15;203:122-127. doi: 10.1016/j.amjcard.2023.06.105. Epub 2023 Jul 22. Am J Cardiol. 2023. PMID: 37487406 Free article.
29 results